Importantly, PMAIP1 is strongly linked to prognosis and responses to immunotherapy in LUAD, with experimental findings indicating its heightened expression in PRAD and its connection to adverse outcomes. This evidence concerns the gene PMAIP1 and prostate adenocarcinoma.